Skip to content

Pathological Th2 cell activation via STAT6 pathway for pulmonary fibrosis.

Sep 2026 · American Journal of Respiratory Cell and Molecular Biology · 0 citations
Medicine

TL;DR

A CD28-JAK1/STAT6-Th2-monocyte-derived alveolar macrophage pathway is defined as a mechanistic driver of pulmonary fibrosis and nominate CD28 and STAT6 as actionable immunologic targets that could complement existing antifibrotic therapies.

View source

Similar papers

Review Open access Aug 2026

Pathogenic group 2 innate lymphoid cells as drivers of lung fibrosis in severe asthma

Severe asthma is characterized by persistent airway inflammation, irreversible airway remodeling, and reduced responsiveness to glucocorticoids. Subepithelial fibrosis, a major determinant of progressive lung function decline, remains mechanistically undefined. Evidence identifies group 2 innate lymphoid cells (ILC2s)...

Masaya Matsuda, Yuya Sannomiya, Osamu Kaminuma et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.